2000 OPEN FORUM Abstracts
INO in Cardiac Disease
Peter Betit, RRT Children's Hospital, Boston, Massachusetts
The administration of inhaled nitric oxide (INO) in the management of cardiopulmonary disease has been intensely studied over the last decade with somewhere in the order of 25,000 scientific papers being published. The use of INO in the diagnosis and treatment of pulmonary hypertension associated with cardiac disease has been one area of ongoing research. Pulmonary hypertension associated with congenital heart disease can greatly influence the timing, type, and success of surgical interventions. Diagnostic testing with INO provides clinicians with valuable information regarding the reactivity of the pulmonary vasculature and helps guide medical and surgical treatment decisions. In the postoperative period, INO has been used to minimize pulmonary hypertensive crisis in children, and allowed for improved recovery. INO has also been used in the evaluation of adult and pediatric heart transplant candidates in which pulmonary hypertension may compromise transplantation. Further research in adults includes comparison of INO to traditional pulmonary vasodilators in the management of postoperative pulmonary hypertension, and the effect of INO on acute right heart syndrome. Another growing area of research is the effect that nitric oxide has on remodeling the pulmonary vasculature and the potential reversal of pulmonary hypertension after long-term inhalation. This presentation will explore some of the current literature related to INO in cardiac disease in children and adults.